Clinical Trials Browser

Phase 2 × HTLV-I Infections × Nivolumab × Clear all

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03075553 2020-04-21

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Immunoblastic Lymphadenopathy, Mycosis Fungoides, HTLV-I Infections, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Clinical Trials

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma